Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management. Many patients wonder whether Mounjaro increases metabolism—specifically, whether it raises the number of calories burned at rest. Whilst Mounjaro does not function as a traditional metabolic stimulant, it influences multiple metabolic pathways through enhanced insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. These mechanisms improve metabolic health and facilitate weight loss primarily through reduced caloric intake rather than increased energy expenditure. Understanding the distinction between direct metabolic stimulation and optimised metabolic function is essential for setting realistic treatment expectations.
Quick Answer: Mounjaro does not directly increase basal metabolic rate but optimises metabolic function through improved insulin sensitivity, glucagon suppression, and appetite regulation, leading to weight loss primarily via reduced caloric intake.
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. It is administered as a once-weekly subcutaneous injection with a gradual dose titration schedule. Mounjaro represents a novel class of medication known as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Metabolism refers to the complex biochemical processes by which the body converts food and drink into energy. This encompasses both basal metabolic rate (BMR)—the energy expended at rest to maintain vital functions—and the additional energy used during physical activity and digestion. Various factors influence metabolic rate, including age, sex, body composition, hormonal status, and genetic factors.
When patients ask whether Mounjaro increases metabolism, they are typically enquiring whether the medication directly raises the number of calories their body burns at rest or during activity. Understanding the distinction between direct metabolic effects and indirect consequences of weight loss is crucial. Mounjaro's primary mechanisms involve enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite—all of which contribute to improved glycaemic control and weight reduction.
The relationship between Mounjaro and metabolism is multifaceted. Whilst the medication does not function as a traditional metabolic stimulant (such as thyroid hormones or sympathomimetic agents), it influences various metabolic pathways that collectively affect energy balance and body composition. This article examines the evidence surrounding Mounjaro's effects on metabolic function, drawing on clinical trial data and mechanistic studies to provide a comprehensive, evidence-based perspective.
Mounjaro exerts its effects through dual agonism of GIP and GLP-1 receptors, which are incretin hormones naturally produced in the gastrointestinal tract in response to food intake. These receptors are found throughout the body, including in pancreatic beta cells, the brain, adipose tissue, and muscle.
The medication's primary metabolic actions include:
Enhanced insulin secretion: Tirzepatide stimulates glucose-dependent insulin release from pancreatic beta cells, improving glucose uptake by tissues and reducing hepatic glucose production
Glucagon suppression: By inhibiting glucagon secretion, Mounjaro reduces the liver's production of glucose, particularly in the fasted state
Delayed gastric emptying: Slowing the rate at which food leaves the stomach affects nutrient absorption and postprandial glucose excursions
Central appetite regulation: Acting on receptors in the hypothalamus and other brain regions, tirzepatide reduces hunger and increases satiety
These mechanisms do not directly increase basal metabolic rate in the manner of thermogenic agents. However, they fundamentally alter energy homeostasis. Improved insulin sensitivity resulting from weight loss and better glycaemic control can optimise metabolic function and nutrient utilisation. Clinical studies show that while most weight loss with tirzepatide comes from fat mass, some reduction in lean body mass also occurs. Maintaining physical activity, particularly resistance training, and ensuring adequate protein intake can help preserve muscle tissue during weight loss.
The GIP component of Mounjaro may have particular relevance to metabolic function. GIP receptors in adipose tissue influence lipid metabolism and may affect how the body stores and utilises fat. Some preclinical research has hypothesised that GIP agonism might influence energy expenditure in brown adipose tissue, though it is important to note that this remains theoretical, and the clinical relevance in humans has not been established.
The pivotal clinical trials evaluating Mounjaro—including the SURPASS programme for type 2 diabetes and the SURMOUNT trials for weight management—have primarily focused on glycaemic control and weight loss outcomes rather than direct measurements of metabolic rate. There is no official link established between Mounjaro and a direct increase in basal metabolic rate based on current published evidence.
Studies measuring resting energy expenditure (REE) in patients taking GLP-1 receptor agonists have produced mixed results. Some research indicates that REE decreases proportionally with weight loss, as would be expected when body mass reduces. A smaller body requires fewer calories to maintain basic functions. However, the magnitude of REE reduction may be less than predicted based on weight loss alone, suggesting some preservation of metabolic rate.
In the SURMOUNT-1 trial, participants receiving the highest dose of tirzepatide (15 mg weekly) achieved mean weight reductions of approximately 20.9% over 72 weeks. Whilst metabolic rate was not directly measured, body composition analyses revealed that a substantial proportion of weight loss came from fat mass, with some loss of lean tissue as well. The SURMOUNT-1 trial demonstrated that approximately 75-80% of weight loss was from fat tissue, which is metabolically significant as muscle tissue is more metabolically active than adipose tissue.
Improvements in metabolic markers observed across clinical trials include enhanced insulin sensitivity, reduced inflammatory markers (such as C-reactive protein), improved lipid profiles, and decreased liver fat content. These changes reflect improved metabolic health rather than increased metabolic rate per se. The distinction is important: Mounjaro optimises how efficiently the body processes nutrients and regulates energy stores, which differs from simply burning more calories at rest.
The substantial weight loss achieved with Mounjaro results primarily from reduced caloric intake rather than increased energy expenditure. Clinical trials demonstrate that tirzepatide significantly decreases appetite and food consumption, leading to a sustained negative energy balance. Participants in the SURMOUNT trials reported reduced hunger and increased feelings of fullness, as measured by validated appetite assessment tools.
During weight loss, the body typically undergoes metabolic adaptation—a phenomenon where metabolic rate decreases beyond what would be predicted by the loss of body mass alone. This adaptive thermogenesis can make further weight loss more difficult and contribute to weight regain. Whether medications like Mounjaro might influence this adaptation remains an area of ongoing research, and definitive conclusions cannot yet be drawn from the available evidence.
The medication's effects on energy expenditure appear to be indirect:
Improved insulin sensitivity enhances cellular glucose uptake and utilisation, potentially improving metabolic efficiency
Reduced inflammation associated with weight loss and improved glycaemic control may normalise metabolic function
Changes in adipokine secretion (hormones produced by fat tissue) can influence whole-body metabolism
Changes in body composition affect overall energy requirements, with the proportion of fat versus lean mass loss being an important factor
Some patients report feeling more energetic whilst taking Mounjaro, which may facilitate greater physical activity. This subjective improvement likely reflects better glycaemic control, reduced inflammation, and psychological benefits of weight loss rather than a direct stimulant effect. Increased physical activity would contribute to total daily energy expenditure, though this represents behavioural change facilitated by the medication rather than a pharmacological increase in metabolic rate.
It is important to note that individual responses vary considerably. Some patients experience more pronounced improvements in energy and activity levels than others, influenced by baseline metabolic health, adherence to lifestyle modifications, and genetic factors.
The metabolic effects of Mounjaro vary between individuals due to numerous physiological and lifestyle factors. Understanding these variables helps set realistic expectations and optimise treatment outcomes.
Baseline metabolic health significantly influences response. Patients with more severe insulin resistance, higher baseline HbA1c, or greater visceral adiposity may experience more pronounced improvements in metabolic markers. Conversely, those with relatively preserved metabolic function may see smaller changes in metabolic parameters despite achieving weight loss.
Body composition plays a crucial role. Individuals with higher proportions of lean muscle mass typically maintain higher metabolic rates. The extent to which lean tissue is preserved during weight loss varies, influenced by:
Protein intake: Adequate dietary protein supports muscle preservation, with requirements ideally calculated using adjusted body weight rather than actual weight, particularly in obesity. A dietitian can provide individualised advice, especially for those with kidney disease
Resistance exercise: Strength training helps maintain or build muscle mass during caloric restriction, as recommended in the UK Chief Medical Officers' Physical Activity Guidelines
Rate of weight loss: Gradual weight reduction generally preserves lean tissue better than rapid loss
Age and sex affect metabolic response. Older adults naturally have lower metabolic rates and may experience greater age-related muscle loss during weight reduction. Women typically have lower basal metabolic rates than men due to differences in body composition and hormonal factors. These physiological differences do not diminish Mounjaro's efficacy but may influence the magnitude of metabolic changes.
Concurrent medications can interact with metabolic pathways. Certain medications may influence metabolic responses, whilst metformin may have complementary effects on insulin sensitivity. Thyroid function must be considered, as hypothyroidism directly reduces metabolic rate and should be optimised before attributing metabolic changes solely to Mounjaro.
Lifestyle factors remain paramount. Patients who combine Mounjaro with regular physical activity (150+ minutes of moderate activity weekly, including resistance training), adequate sleep (7–9 hours nightly), stress management, and a balanced diet typically achieve better metabolic outcomes than those relying on medication alone.
Whilst Mounjaro does not increase metabolism in the manner of stimulant medications, patients require appropriate monitoring to ensure safe and effective treatment. The MHRA-approved Summary of Product Characteristics (SmPC) outlines essential safety considerations.
Common adverse effects include gastrointestinal symptoms—nausea, vomiting, diarrhoea, and constipation—which typically diminish over time. These effects can temporarily affect nutritional intake and should be managed to prevent excessive muscle loss. Patients experiencing persistent vomiting or inability to maintain adequate hydration should contact their GP promptly.
Metabolic monitoring should include:
HbA1c and fasting glucose: Assessed every 3–6 months in patients with diabetes to evaluate glycaemic control
Renal function: Assessed when clinically indicated, particularly with severe gastrointestinal adverse effects or in patients with pre-existing renal impairment
Lipid profile: Monitored as weight loss typically improves cholesterol levels
Liver function tests: Particularly relevant in patients with non-alcoholic fatty liver disease
Thyroid considerations: The SmPC includes a warning regarding thyroid C-cell tumours observed in rodent studies. Whilst the relevance to humans remains uncertain, patients should be counselled to report any symptoms such as neck lumps, hoarseness, or difficulty swallowing. This is a precaution rather than a formal contraindication in the UK.
Hypoglycaemia risk increases when Mounjaro is combined with insulin or sulphonylureas. Dose adjustments of these medications may be necessary. Patients should be educated on recognising and managing low blood glucose.
Pregnancy and breastfeeding: Mounjaro is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception while taking tirzepatide.
Nutritional adequacy becomes crucial during significant weight loss. Referral to a dietitian can help ensure adequate protein, micronutrient intake, and sustainable eating patterns. NICE guidance recommends multidisciplinary support for weight management, including behavioural interventions alongside pharmacotherapy.
Patients should seek immediate medical advice if they experience severe abdominal pain (potential pancreatitis, in which case tirzepatide should be discontinued), visual changes (diabetic retinopathy complications), or signs of gallbladder disease. Regular follow-up with healthcare professionals ensures that metabolic improvements are sustained and any adverse effects are promptly addressed. Suspected adverse reactions should be reported through the MHRA Yellow Card Scheme.
Mounjaro does not directly increase basal metabolic rate like stimulant medications. Instead, it optimises metabolic function by improving insulin sensitivity, reducing inflammation, and facilitating weight loss primarily through appetite suppression and reduced caloric intake.
Mounjaro causes weight loss mainly by reducing appetite and increasing feelings of fullness, leading to decreased food intake. It also slows gastric emptying and improves glucose regulation, creating a sustained negative energy balance without directly raising metabolic rate.
Yes, combining Mounjaro with regular resistance exercise and adequate protein intake helps preserve lean muscle mass during weight loss. A dietitian can provide personalised nutritional guidance to support muscle preservation alongside fat loss.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
